ArticleJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society2010
Prevalence and risk factors for recovery of filamentous fungi in individuals with cystic fibrosis.
Article in Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 1 synthesis or guideline pooled it, 129 citations in OpenAlex.
- Biologic drugs in treating allergic bronchopulmonary aspergillosis in patients with cystic fibrosis: a systematic review.European respiratory review : an official journal of the European Respiratory Society · 2022Pooled it
- Home sputum collection forERJ open research · 2025Article
- How to Assess Fungal Contamination of Indoor Air in Dwellings of Patients with Cystic Fibrosis?Mycopathologia · 2025Article
- Distinct airway mycobiome signature in patients with pulmonary hypertension and subgroups.BMC medicine · 2025Article
- Increased NFAT and NFκB signalling contribute to the hyperinflammatory phenotype in response to Aspergillus fumigatus in a mouse model of cystic fibrosis.PLoS pathogens · 2025Article
- The Real-World Effectiveness of Antifungals in People with Cystic Fibrosis andAnnals of the American Thoracic Society · 2025Article
- MycoKeys · 2025Article
- Exploring the dynamics of mixed-species biofilms involving Candida spp. and bacteria in cystic fibrosis.Archives of microbiology · 2024Review
- In host evolution of Exophiala dermatitidis in cystic fibrosis lung micro-environment.G3 (Bethesda, Md.) · 2023Article
- Distinct community structures of the fungal microbiome and respiratory health in adults with cystic fibrosis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2023Article
- The Clinical Association betweenAnnals of the American Thoracic Society · 2023Article
- Article
- Upper respiratory tract mycobiome alterations in different kinds of pulmonary disease.Frontiers in microbiology · 2023Article
- A cooperativity between virus and bacteria during respiratory infections.Frontiers in microbiology · 2023Review
- Detection of Opportunistic Fungi from the Bronchoalveolar Lavage Specimens of Patients with Pulmonary Diseases.Advanced biomedical research · 2023Article
- Potential Antifungal Targets forInternational journal of molecular sciences · 2022Review
- The Human Mycobiome in Chronic Respiratory Diseases: Current Situation and Future Perspectives.Microorganisms · 2022Review
- Clinical characteristics of people with cystic fibrosis and frequent fungal infection.Pediatric pulmonology · 2022Article
- Emerging Fungal Threats in Cystic Fibrosis.Mycopathologia · 2021Review
- Fungal Infection and Inflammation in Cystic Fibrosis.Pathogens (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
backgroundFilamentous fungi are frequently recovered from respiratory cultures of individuals with CF.
methodsA CF cohort database was utilized to determine filamentous fungal prevalence and risk factors.
resultsThe prevalence of filamentous fungal isolation increased from 2.0% in 1997 to 28.7% in 2007. The odds of isolating filamentous fungi during a quarter was greater in CF adults [p<0.001], during chronic oral antibiotic use [p=0.002] and increased with each 10% drop in FEV(1) percent predicted [p=0.005], while inhaled corticosteroids surprisingly decreased the likelihood [p=0.012]. The direction of these effects persisted after excluding individuals with ABPA. A sub-analysis determined older age [p=0.019] and use of inhaled antibiotics [p=0.011] were independent risk factors for onset of fungal colonization.
conclusionsThis study suggests that isolation of filamentous fungi in CF at JHH has increased and risk factors include older age, decreased lung function, and chronic oral antibiotics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.